Crossmark

Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

Crossref DOI link: https://doi.org/10.1007/s11864-019-0639-0

Published Online: 2019-05-03

Published Print: 2019-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Martinez Chanza, Nieves

Tripathi, Abhishek

Harshman, Lauren C.
License Information

Text and Data Mining valid from 2019-05-01
More Information

Article History

First Online: 3 May 2019

Compliance with Ethical Standards

:

: Nieves Martinez Chanza has received compensation from Bayer for participation on advisory boards and has received reimbursement for travel expenses from Pfizer.Abhishek Tripathi declares that he has no conflict of interest.Lauren C. Harshman has received research funding (paid to her institution) from Bayer, Sotio, Bristol-Myers Squibb, Merck, Takeda, Dendreon/Valeant, Janssen, Medivation/Astellas, Genentech, and Pfizer; has received compensation for participation on advisory boards from Bayer, Genentech, Dendreon, Pfizer, Medivation/Astellas, Merck, Exelixis, Corvus, Novartis, EMD Serono and Jounce Therapeutics; and has received reimbursement for travel expenses from Bayer.

: This article does not contain any studies with human or animal subjects performed by any of the authors.